A Synthetic Peptide Fragment Derived from RANTES is a Potent Inhibitor of HIV-1 Infectivity Despite a Surprising Lack of CCR5 Receptor Affinity |
| |
Authors: | Ramnarine Emabelle DeVico Anthony L. Vigil-Cruz Sandra C. |
| |
Affiliation: | (1) Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA;(2) Present address: ALZA Corporation, Mountain View, CA, USA;(3) Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD, USA;(4) Present address: Department of Medicinal Chemistry, University of Kansas, Lawrence, KS, USA |
| |
Abstract: | Summary CCR5 (CC-chemokine receptor 5) is a key co-receptor, in concert with CD4, for infectivity of HIV-1 (human immunodeficiency virus type-1) into healthy human cells, and RANTES, an endogenous ligand for CCR5, is a potent inhibitor of HIV-1 infectivity. In this structure-activity relationship (SAR) study, peptide fragments derived from RANTES were designed, synthesized and evaluated for their ability to inhibit HIV-1 infectivity. The goal was to determine the effect of peptide length on anti-HIV activity and to obtain an optimally sized RANTES peptide probe for further SAR studies. The analogue Ac[Ala10,11]RANTES-(1–14)NH2, AA14, was identified as an effective inhibitor of HIV-1 infectivity at 10 nM but despite the functional activity, surprisingly it did not exhibit any notable affinity for the CCR5 chemokine receptor. Further, increasing peptide size enhanced neither the inhibition of HIV-1 infectivity nor CCR5 receptor affinity. As a potent inhibitor of HIV-1 infectivity, the lead analogue most likely utilizes a different (and currently unknown) mechanism than interaction with CCR5 for anti-HIV activity. |
| |
Keywords: | CCR5 chemokine receptor chemokine HIV-1 infectivity peptide design and synthesis RANTES structure-activity relationship study |
本文献已被 SpringerLink 等数据库收录! |
|